Aurobindo to incur Rs 300 cr capital expenditureIllustrative image – not actual.

Hyderabad-based drug maker, Aurobindo Pharma (APL), will incur about Rs 300 crore as capital expenditure, including maintenance expense in the current financial year.

 

The capital expenditure of the company will be separate from the investments made in acquisitions so far this year.

 

This year, Aurobindo made strategic acquisitions and investments in Hyderabad-based Celon Labs to enter the oncology and hormones space and Silicon Life Sciences for ensuring supplies of penem non-sterile active pharmaceutical ingredients (APIs) to feed into AuroNext, a joint venture between APL and BR Sikri Associate of the ABS Group.

 

The company has also acquired Hyacinths Pharma (having 52 acre of land) with all statutory clearances in place, for future expansion. The cost of these acquisitions is in the range of Rs 60-70 crore.

 

Besides, the commercial facility of Auro Peptides, a subsidiary of APL, is presently ready with two modules.

 

The company is expected to file its first product before the end of this financial year which will trigger an inspection of the facility by various regulators.

← All latest storiesBack to top →